← Browse by Condition
Medical Condition

estrogen receptor positive her2 negative advanced breast cancer

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

ClinicalMetric aggregates all active clinical trials for estrogen receptor positive her2 negative advanced breast cancer from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries. Trials are updated daily as new studies open, status changes, and enrollment targets are updated.

  • Recruiting trials — currently enrolling participants, with eligibility criteria
  • Phase 1–4 studies — from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary for every trial listing
NCT06065748 Phase 3
Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Enrollment
1,050 pts
Location
United States, Argen...
Sponsor
Hoffmann-La Roche
View Trial →